Workflow
Theratechnologies Reports Financial Results for the First Quarter 2025 and Reviews Key Achievements
THTarget Hospitality(TH) GlobeNewswire·2025-04-09 11:30

Core Insights - Theratechnologies reported a total revenue of 19millionforQ12025,reflectingayear−over−yeargrowthof1719 million for Q1 2025, reflecting a year-over-year growth of 17% [2][14] - The company achieved a net profit of 117,000, a significant improvement from a net loss of 4.48millioninQ12024[28]−TheapprovalofEGRIFTAWR™bytheFDAisexpectedtoenhancethecompany′sgrowthtrajectoryintheHIVtreatmentmarket[3][35]FinancialPerformance−EGRIFTASVnetsalesreached4.48 million in Q1 2024 [28] - The approval of EGRIFTA WR™ by the FDA is expected to enhance the company's growth trajectory in the HIV treatment market [3][35] Financial Performance - EGRIFTA SV net sales reached 13.88 million, up 44.8% from 9.59millioninQ12024,primarilyduetohigherunitsalesandapriceincrease[2][15]−Trogarzosalesdecreasedby22.49.59 million in Q1 2024, primarily due to higher unit sales and a price increase [2][15] - Trogarzo sales decreased by 22.4% to 5.17 million, attributed to lower unit sales and increased government rebates [2][17] - Adjusted EBITDA for Q1 2025 was 2.32million,comparedtoalossof2.32 million, compared to a loss of 247,000 in the same period last year, indicating improved operational efficiency [26] Recent Developments - The FDA approved the supplemental Biologics License Application for EGRIFTA WR™ on March 25, 2025, which is anticipated to drive further adoption [3][35] - The company faced a temporary supply disruption for EGRIFTA SV due to a manufacturing shutdown, but resumed distribution on February 14, 2025 [6][34] - The approval of the Prior Approval Supplement (PAS) for EGRIFTA SV on April 7, 2025, allows for regular distribution without further FDA authorization [9][35] Research and Development - R&D expenses decreased by 21.2% to 2.97millioninQ12025,mainlyduetoreducedspendingonlife−cyclemanagementprojects[20]−ThecompanypresenteddatahighlightingthelimitationsofusingBMItoassesscardiovascularriskinpeoplewithHIV,emphasizingtheneedforbetterscreeningmethods[10]GuidanceandFutureOutlook−ThecompanyestimatesFY2025revenuetobebetween2.97 million in Q1 2025, mainly due to reduced spending on life-cycle management projects [20] - The company presented data highlighting the limitations of using BMI to assess cardiovascular risk in people with HIV, emphasizing the need for better screening methods [10] Guidance and Future Outlook - The company estimates FY2025 revenue to be between 80 million and $83 million, considering the impact of the supply disruption and the new product launch [12] - The transition from EGRIFTA SV to EGRIFTA WR™ is crucial for meeting financial covenants and sustaining revenue growth [36]